曾凤,卢亚梅,周元清,陈永铃.氯替泼诺治疗中重度干眼抗炎作用的临床分析.[J].中南医学科学杂志.,2013,41(5):486-489. |
氯替泼诺治疗中重度干眼抗炎作用的临床分析 |
Clinical Research of Anti-inflammatory Effects of LoteprednolTreat Moderate to Severe Dry Eye |
投稿时间:2013-05-09 |
DOI: |
中文关键词: 干眼 氯替泼诺 炎症介质 |
英文关键词:dry eye loteprednol inflammatory mediators |
基金项目: |
|
摘要点击次数: 1150 |
全文下载次数: 1879 |
中文摘要: |
目的观察0.5%氯替泼诺滴眼液治疗中重度干眼病的临床疗效。方法按标准纳入中重度干眼患者40例,回顾性分两组:联合用药组予0.5%氯替泼诺滴眼液和新泪然滴眼液联合用药;单用药组用新泪然滴眼液。在治疗前及治疗后2、4、6周观察眼表疾病指数(OSDI)、泪膜破裂时间(BUT)、泪液分泌实验(Schirmer I试验)、眼表染色评分(OSS评分)、眼压;ELISA测泪液中炎症介质白介素-6(IL-6)的表达。结果治疗2周后,联合用药组OSDI评分均值明显降低,较治疗前差异有显著性(P<0.05);治疗2周联合用药组眼表炎症体征减轻;联合用药组BUT均较治疗前延长;两组各时间点的Sehirmer I及眼压值无明显变化。结论0.5%氯替泼诺滴眼液通过下降IL-6表达,减轻中重度干眼眼表炎症,安全有效。 |
英文摘要: |
ObjectiveTo observe the effect of 0.5% loteprednol eye drops on the clinical efficacy of moderate-severe dry eye and investigate the potential mechanism of loteprednol eye drops in anti-inflammation.Method40 cases of moderate-severe dry eye patients according to the clinical standards were randomly divided into two groups:Experimental group (0.5% loteprednol eye drops together with Hypromellose 2910 eye drops);The control (Hypromellose 2910 eye drops).After treatment of loteprednol eye drops for 2,4,6weeks,and ocular Surface Disease Index(OSDI),tear film break-up time(BUT),Schirmer test I(Schirmer I test),ocular surface staining(OSS) score and intraocular pressure were observed,the IL-6 expression in the tear fluid was detected by Enzyme-linked immunosorbent assay (ELISA).ResultAfter two weeks of treatment,the OSDI mean score of experimental group was significantly reduced,the difference was statistically significant(P<0.05) than before treatment,and ocular inflammation signs of experimental group was alleviated;BUT of Experimental group was extended than before treatment;Sehirmer I and NCT in two groups at each time point were not significantly changed.Conclusions0.5% loteprednol eye drops could decrease the expression of IL-6 and relieve the symptom of moderate to severe dry eye ocular inflammation;so it is safe and effective. |
查看全文 查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|